CombiMatrix Appoints Preeminent Pediatric Neurologist Dr. James W. Wheless to its Scientific Advisory Board
February 02 2017 - 6:00AM
CombiMatrix Corporation (NASDAQ:CBMX), a family health molecular
diagnostics company specializing in DNA-based reproductive health
and pediatric testing services, announces that James W. Wheless,
M.D., FAAP, FAAN, has joined its Scientific Advisory Board.
Dr. Wheless is Professor and Chief of Pediatric Neurology at the
University of Tennessee Health Science Center, and is Director of
the Neurosciences Institute and Director of Comprehensive Epilepsy
Program at Le Bonheur Children’s Hospital in Memphis, Tenn.
“We are delighted to have Dr. Wheless, a
renowned leader in pediatric neurology, become the newest member of
our Scientific Advisory Board (SAB),” said Mark McDonough,
President and Chief Executive Officer of CombiMatrix. “Dr.
Wheless brings a fresh perspective in neurology to our SAB, which
has already made meaningful contributions in supporting the
adoption of our tests. We look forward to tapping into Dr.
Wheless’ significant expertise as we develop strategies to further
improve our market presence, expand our test portfolio and improve
family health diagnostic care.”
“Major advances in pediatric neurology over the
past decade have come from the adoption of newer technologies such
as chromosomal microarray analysis in prenatal and pediatric
testing that allows for the detection of smaller chromosomal
variants over karyotyping,” said Dr. Wheless. “Better
detection of neurologic disorders is part of a comprehensive
approach to improving the lives of pediatric patients and I’m
delighted to provide my expertise to further support quality
care.”
Dr. Wheless is a Diplomat of the American Board
of Pediatrics and the American Board of Psychiatry and Neurology
with special qualifications in child neurology, clinical
neurophysiology and epilepsy. He is a fellow of the American
Academy of Pediatrics and the American Academy of Neurology.
He has been a member of the editorial boards of numerous
peer-reviewed journals and is a current member at the Journal of
Child Neurology and Neurotherapeutics. He has written three
books and more than 50 chapters related to pediatric neurology, and
has authored more than 450 articles published in peer-reviewed
journals and abstracts presented at scientific conferences.
He has received numerous awards and honors, including “Who’s Who in
Medicine and Healthcare,” “Who’s Who in the World” and “Best
Doctors in America.” Dr. Wheless received his M.D. from the
University of Oklahoma, and completed residencies in pediatrics at
the University of Oklahoma and in pediatric neurology at
Northwestern University at Children’s Memorial Hospital in
Chicago.
About CombiMatrix
Corporation
CombiMatrix Corporation provides best-in-class
molecular diagnostic solutions and comprehensive clinical support
to foster the highest quality in patient care. CombiMatrix
specializes in pre-implantation genetic diagnostics and screening,
prenatal diagnosis, miscarriage analysis and pediatric
developmental disorders, offering DNA-based testing for the
detection of genetic abnormalities beyond what can be identified
through traditional methodologies. Our testing focuses on advanced
technologies, including single nucleotide polymorphism chromosomal
microarray analysis, next-generation sequencing, fluorescent in
situ hybridization and high resolution karyotyping.
Additional information about CombiMatrix is available at
www.combimatrix.com or by calling (800) 710-0624.
Safe Harbor Statement under the Private
Securities Litigation Reform Act of 1995
This press release contains forward-looking
statements within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995. These
statements are based upon our current expectations, speak only as
of the date hereof and are subject to change. All statements, other
than statements of historical fact included in this press release,
are forward-looking statements. Forward-looking statements can
often be identified by words such as "anticipates," “approximates,”
"expects," "intends," "plans," "goal," "predicts," "believes,"
"seeks," "estimates," "may," "will," "should," "would," "could,"
"potential," "continue," "ongoing," similar expressions, and
variations or negatives of these words and include, but are not
limited to, statements regarding projected results of operations,
including projected cash flow-positive operating results,
management's future business, operational and strategic plans,
recruiting efforts and test menu expansion. These forward-looking
statements are not guarantees of future results and are subject to
risks, uncertainties and assumptions that could cause our actual
results to differ materially and adversely from those expressed in
any forward-looking statement. The risks and uncertainties referred
to above include, but are not limited to: our estimates of total
market sizes for the tests that we offer; our ability to grow
revenue and improve gross margin; delays in achieving cash
flow-positive operating results; the risk that test volumes and
reimbursements level off or decline; the risk that payors decide to
not cover our tests or to reduce the amounts they are willing to
pay for our tests; the risk that we will not be able to grow our
business as quickly as we need to; the inability to raise capital;
the loss of members of our sales force; our ability to successfully
expand the base of our customers, add to the menu of our diagnostic
tests, develop and introduce new tests and related reports, expand
and improve our current suite of diagnostic services, optimize the
reimbursements received for our molecular testing services, and
increase operating margins by improving overall productivity and
expanding sales volumes; our ability to successfully accelerate
sales, steadily increase the size of our customer rosters in all of
our genetic testing markets; our ability to attract and retain
a qualified sales force in wider geographies; our ability to ramp
production from our sales; rapid technological change in our
markets; changes in demand for our future services; legislative,
regulatory and competitive developments; general economic
conditions; and various other factors. Further information on
potential factors that could affect our financial results is
included in our Annual Report on Form 10-K, Quarterly Reports of
Form 10-Q, and in other filings with the Securities and
Exchange Commission. We undertake no obligation to revise or update
publicly any forward-looking statements for any reason, except as
required by law.
Company Contact: |
|
|
|
|
Investor Contact: |
Mark McDonough |
|
|
|
|
LHA |
President & CEO,
CombiMatrix Corporation |
|
|
|
|
Jody Cain |
(949) 753-0624 |
|
|
|
|
(310) 691-7100 |
|
|
|
|
|
jcain@lhai.com |
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Historical Stock Chart
From Apr 2023 to Apr 2024